Session Information
2012 Midyear Clinical Meeting
Click here to go to the previous page
Therapeutic Dilemmas in PK/PD, Pneumonia and Multi-Drug Resistance: Crossroads Between ID and ICU
Track:
New Practitioners Sessions (CE)
Program Code: 312-L01
Date: Sunday, December 2, 2012
Time: 1:00 PM to 3:00 PM EST
Location:
South Seas B, Level 3, South Convention Center
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Christine Kubin, PharmD, BCPS (AQ-ID), Clinical Pharmacy Manager, Infectious Diseases, NewYork-Presbyterian Hospital
PROGRAM CHAIR:
Simon Lam
Description
Antimicrobial Pharmacokinetics/Pharmacodynamics in Critically Ill Patients, Meghan Jeffres, PharmD
Updates in HAP, HCAP, and VAP, Garrett W. Schramm, PharmD, BCPS
Treatment and Risk Factors of Multi-Drug Resistant Gram Negative Pathogens, Christine J. Kubin, PharmD, BCPS (AQ-ID)
Role of Early Antifungal Therapy in Critically Ill Patients: Risk Factors and Treatment Options, Simon W. Lam, PharmD, BCPS
Updates in HAP, HCAP, and VAP, Garrett W. Schramm, PharmD, BCPS
Treatment and Risk Factors of Multi-Drug Resistant Gram Negative Pathogens, Christine J. Kubin, PharmD, BCPS (AQ-ID)
Role of Early Antifungal Therapy in Critically Ill Patients: Risk Factors and Treatment Options, Simon W. Lam, PharmD, BCPS
- Apply recent evidence in hospital acquired pneumonia, healthcare associated pneumonia, and ventilator associated pneumonia to optimize patient pharmacotherapy.
- Assess the role of early antifungal therapy in critically ill patients.
- Evaluate the epidemiological trends, risk factors, and treatments of multi-drug resistant gram negative pathogens.
- Identify antibiotic pharmacokinetic differences in critically ill patients and the development of dosing regimens to meet pharmacodynamic goals.
This session is a part of:
This session is a part of: